Transsphenoidal surgery (TSS) is the most common first-line treatment for Cushing's disease (CD). We have examined the outcome of this intervention to identify pre-operative clinical factors that predict good surgical outcome and to determine the risk of adverse events.
In conclusion, remission rates for CD from this unit are comparable to other published series. Taken together, unequivocal dynamic endocrine testing and a positive MRI scan predict remission following TSS (8/8). Patients who meet neither criteria require further assessment before proceeding to TSS, as only 11/20 (55%) enter remission (p=0.03) and the risk of panhypopituitarism is high.
08 - 11 Apr 2002
British Endocrine Societies